The earnings call reflects a strong positive sentiment due to significant revenue growth, a turnaround in operating profits, and expansion of the pipeline. However, there are some concerns about inventory impacts on revenue and potential market disruptions.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call, Pharming's CEO, Fabrice Chouraqui, highlighted a robust financial performance marked by a 26% increase in total revenues compared to the same quarter the previous year. The company reported an operating profit of $12.9 million, excluding $2 million in nonrecurring expenses related to the Abliva acquisition. RUCONEST and Joenja drove this growth, with RUCONEST revenues rising by 28% year-over-year and Joenja patient uptake accelerating significantly. Pharming upgraded its full-year revenue guidance to $335-350 million, anticipating 13-18% growth, and reported a strong cash position of $130.8 million, up from $108.9 million in Q1 2025. The company is also expanding its pipeline, with Joenja's geographic and pediatric expansion, and the development of KL1333 for mitochondrial disease.

Strong Revenue Growth

Pharming delivered a very strong quarter with total revenues growing by 26% in the second quarter of 2025 versus the same quarter last year, fueled by significant growth of RUCONEST and Joenja.

Operating Profit Turnaround

The company reported a meaningful operating profit of $12.9 million compared to a loss in the previous year.

RUCONEST and Joenja Performance

RUCONEST experienced a 28% year-on-year growth, while Joenja saw a strong double-digit revenue growth quarter-on-quarter of 15%.

Pipeline Expansion

Pharming's pipeline includes the ongoing development of Joenja in larger indications and the addition of KL1333 from the Abliva acquisition, which has passed an interim analysis in a registrational trial.

Financial Position

Cash and marketable securities increased significantly, indicating strong cash flow generation from operating activities.

Pharming Group (PHAR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHAR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	<0.01 / -	-0.02	―	―	―
Jul 31, 2025	2025 (Q2)	-0.10 / 0.06	-0.02	400.00% (+0.08)
May 08, 2025	2025 (Q1)	-0.03 / -0.22	-0.19	-15.79% (-0.03)
Mar 13, 2025	2024 (Q4)	0.02 / 0.05	-0.04	225.00% (+0.09)
Oct 24, 2024	2024 (Q3)	>-0.01 / -0.02	0.005	-500.00% (-0.03)
Aug 01, 2024	2024 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 08, 2024	2024 (Q1)	<0.01 / -0.19	-0.17	-11.76% (-0.02)
Mar 14, 2024	2023 (Q4)	<0.01 / -0.04	-0.205	80.49% (+0.16)
Oct 26, 2023	2023 (Q3)	-0.13 / <0.01	0.4	-98.75% (-0.40)
Aug 03, 2023	2023 (Q2)	-0.10 / 0.01	0.215	-95.35% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHAR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$10.09	$11.11	+10.11%
May 08, 2025	$9.00	$10.01	+11.22%
Mar 13, 2025	$7.74	$8.74	+12.92%
Oct 24, 2024	$8.96	$8.30	-7.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (PHAR) report earnings?

Pharming Group (PHAR) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Pharming Group (PHAR) earnings time?

Pharming Group (PHAR) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHAR EPS forecast?

PHAR EPS forecast for the fiscal quarter 2025 (Q3) is <0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing